Icon

NORVASC (nda019787)- (EQ 2.5MG BASE,EQ 5MG BASE,EQ 10MG BASE)

AMLODIPINE BESYLATE VIATRIS
EQ 2.5MG BASE,EQ 5MG BASE,EQ 10MG BASE
Yes No
2007-Sep-25 Expired
None None
None No
NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension o NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease o Chronic Stable Angina o Vasospastic Angina (Prinzmetal’s or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%.
20 0 13
Total Other Developers 14
Drugs with Suitability No
EQ 2.5MG BASE ** ** - - 11
EQ 5MG BASE ** ** Up 9 1
EQ 10MG BASE ** ** Up 9 1
NDA Sales Available Total Generic Sales Available
Yes 11
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ***** ***** ******* *** *********** **********, *** ****** ****, *********, ********* ******, ***** (***) ***
****** ***** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ***** ***** ******* *********** **** **. * &** ****** ******* ******** ****, ***** **, ********* ****, ****** ******* ******, ***** (***) ***
****** ***** ***** ******* *********** **** **. *-*, *-**, *-** *** *-**/*/*, ********** ********** ****, ******, *********** ******, ***** (***) ***
****** ******* ****** ******* ******* ******* ******* *********** **** **. ***, ***, ***, *** & ***, ***** ************** *******, *******, ************, ***** **** ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ***** ***** ******* *********** * **-*, **** ********** ****, ***********, **********, *********** ******, ***** (***) ***
****** ***** ****** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ***** ****** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ****** ****** ****** ***************, *** *********** *** **** **** *******, **********, ******* (**) *****, ****** ****** (***) ***
****** ***** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** ***** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ***** *** ****** ******* ******* *********** ****** **. ** ** **, ******* *******, **********, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* *************** ***. *********** ** ******** ***, **** **, ********, *** **** (**) *****, ****** ****** (***) ***
****** ***** ***** ******* *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ******* ******* ************ ******* *********** **** **. ** ** **, ******* ********** ******, *******, ******, *** ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******* ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.